PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in breast cancer since it is highly deregulated in this disease and it also mediates resistance to anti-HER2 therapies. However, initial stud...

Full description

Bibliographic Details
Main Authors: Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, Pieter, Ibrahim, Y.H., Chandarlapaty, S., Markman, B., Rodriguez, O., Guzman, M., Rodriguez, S., Gili, M., Russillo, M., Parra, J.L., Singh, S., Arribas, J., Rosen, N., Baselga, J.
Format: Journal Article
Language:English
Published: NATURE PUBLISHING GROUP 2011
Subjects:
Science & Technology
Life Sciences & Biomedicine
Biochemistry & Molecular Biology
Oncology
Cell Biology
Genetics & Heredity
PI3K/mTOR
HER2
feedback
ERK
BEZ235
PHASE-II
TRASTUZUMAB RESISTANCE
PATHWAY ACTIVATION
ANTITUMOR-ACTIVITY
PTEN
RECEPTOR
PIK3CA
MUTATIONS
GENE
MEK
Online Access:http://hdl.handle.net/20.500.11937/81904

Similar Items

Similar Items